HER2+ Breast Cancer | Specialty

The OncLive Neoadjuvant HER2+ Cancer condition center page is a comprehensive resource for clinical news and expert insights on treatment for patients with HER2-positive breast cancer. This page features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances in both the localized and metastatic settings, and ongoing research in HER2-positive breast cancer.

Expert Recaps Adjuvant Advancements in HER2+ Breast Cancer

May 24th 2018

Haythem Y. Ali, MD, discusses adjuvant advances in HER2-postitive breast cancer and emerging agents in the field.

Dr. Pegram Discusses the Use of Neratinib in HER2+ Breast Cancer

May 23rd 2018

Mark D. Pegram, MD, Susy Yuan-Huey Hung Professor, co-director, Stanford’s Molecular Therapeutics Program, director, Breast Cancer Oncology Program, Stanford Women’s Cancer Center, discusses the use of neratinib (Nerlynx) in the treatment of patients with HER2-positive breast cancer.

Dr. Ali on Choosing Adjuvant Treatment for HER2+ Breast Cancer

May 18th 2018

Haythem Y. Ali, MD, senior medical oncologist, Henry Ford Hospital, discusses the adjuvant treatment of patients with HER2-positive breast cancer.

Shorter Trastuzumab Duration Matches 12-Month Standard for Early HER2+ Breast Cancer

May 17th 2018

A shorter 6-month course of adjuvant trastuzumab (Herceptin) was found to be noninferior for disease-free survival compared with the standard 12-month schedule for patients with HER2-positive early breast cancer.

Dr. Verma on Immunotherapy in HER2+ Breast Cancer

May 14th 2018

Sunil Verma, MD, professor and head of the Department of Oncology at the University of Calgary, medical director of the Tom Baker Cancer Centre, discusses immunotherapy in HER2-positive breast cancer.

Dr. Pegram Discusses Adjuvant Pertuzumab in HER2+ Breast Cancer

May 11th 2018

Mark D. Pegram, MD, Susy Yuan-Huey Hung Professor, co-director, Stanford’s Molecular Therapeutics Program, director, Breast Cancer Oncology Program, Stanford Women’s Cancer Center, discusses the use of adjuvant pertuzumab (Perjeta) in patients with HER2-positive breast cancer.

HER2+ Breast Cancer Outlook Improved, But More Work Remains

May 5th 2018

Kelly McCann, MD, PhD, discusses the therapies available for patients with HER2-positive breast cancer and the potential benefit with additional subtyping in the field.

Findings Clarify Picture for HER2-Positive Breast Cancer

May 1st 2018

A panel of experts discuss the latest developments in the treatment of patients with HER2-positive breast cancer.

Dr. Roussos Torres on the Potential for Immunotherapy in HER2+ Breast Cancer

April 24th 2018

Evanthia Roussos Torres, MD, oncology fellow, Johns Hopkins University School of Medicine, discusses the promise of immunotherapy in the treatment of patients with HER2-positive breast cancer.

New Agents on Horizon for HER2-Positive Breast Cancer

April 12th 2018

There are multiple therapeutic options in development for the treatment of patients with HER2-positive breast cancer, further adding to the regimens available, explains Frances Valdes-Albini, MD.

Dr. Valdes-Albini on the FDA Approval of Adjuvant Pertuzumab in HER2+ Breast Cancer

April 12th 2018

Frances Valdes-Albini, MD, assistant professor of clinical medicine, Sylvester Comprehensive Cancer Center, University of Miami Health System, discusses the FDA approval of adjuvant pertuzumab (Perjeta) in patients with HER2-positive breast cancer.

Dr. Verma Discusses Emerging Agents in HER2+ Breast Cancer

April 12th 2018

Sunil Verma, MD, professor and head of the Department of Oncology at the University of Calgary, medical director of the Tom Baker Cancer Centre, discusses emerging agents for the treatment of HER2-positive breast cancer.

Pegram Highlights Progress in HER2+ Breast Cancer

April 9th 2018

Mark D. Pegram, MD, discusses the evolving treatment paradigm of HER2-positive breast cancer.

Dr. Jahanzeb on the Benefit of Pertuzumab Plus Trastuzumab in HER2+ Breast Cancer

April 5th 2018

Mohammad Jahanzeb, MD, professor of Clinical Medicine, Hematology/Oncology, Sylvester Comprehensive Cancer Center, University of Miami Miller School of Medicine, discusses the benefit of pertuzumab (Perjeta) plus trastuzumab (Herceptin) for patients with HER2-positive breast cancer.

Dr. Durand Discusses Treatment Options for Toxicities from Therapy in HER2+ Breast Cancer

April 2nd 2018

Jean-Bernard Durand, MD, professor in the Department of Cardiology at The University of Texas MD Anderson Cancer Center, discusses advice for community oncologists on managing patients that are experiencing symptoms from treatment for HER2-positive breast cancer.

Dr. Pegram on Developing Agents for Patients With HER2+ Breast Cancer and Brain Metastases

April 2nd 2018

Mark D. Pegram, MD, Susy Yuan-Huey Hung Professor, co-director, Stanford’s Molecular Therapeutics Program, director, Breast Cancer Oncology Program, Stanford Women’s Cancer Center, discusses developing agents for patients with HER2-positive breast cancer who have brain metastases.

Dr. Gradishar Discusses the Treatment of HER2+ Breast Cancer

March 30th 2018

William J. Gradishar, MD, interim chief of hematology and oncology, Department of Medicine, Betsy Bramsen Professorship of Breast Oncology, professor of medicine (hematology and oncology), Northwestern University's Feinberg School of Medicine, discusses the treatment of HER2-positive breast cancer.

Dr. Jahanzeb Discusses Advancements in Adjuvant HER2+ Breast Cancer

March 21st 2018

Mohammad Jahanzeb, MD, professor of Clinical Medicine, Hematology/Oncology, Sylvester Comprehensive Cancer Center, University of Miami Miller School of Medicine, discusses advancements in adjuvant HER2-positive breast cancer.

Optimizing HER2-Targeted Therapy

March 19th 2018

Sara Hurvitz, MD, and Sunil Verma, MD, share their expert insight on the latest groundbreaking developments in HER2-positive breast cancer.

Dr. Durand on Anthracyclines in Treatments for HER2+ Breast Cancer

March 16th 2018

Jean-Bernard Durand, MD, associate professor in the Department of Cardiology at The University of Texas MD Anderson Cancer Center, discusses protecting patients’ hearts from anthracyclines and HER2-targeted therapies when treating for HER2-positive breast cancer.